Teva-Handok Appoints Sun-dong Park From BMS in US HQ, as New CEO

– Teva-Handok recruits Park Sun-dong, former Executive Director of Global Marketing in
  BMS headquarters in US, as its new CEO
– Appointment will be effective as of September 1st

Teva-Handok (Chairman Itzhak Krinsky) announced today that it has appointed Sun-dong Park (age 53), former Executive Director at Bristol-Myers Squibb in the US, as its new CEO. Park served as CEO of BMS Pharmaceutical Korea before his relocation to BMS headquarters in the US as Executive Director of Global Marketing. The appointment will be effective as of September 1st.

Park had worked at JW Pharmaceutical from 1989 to 2000, and joined BMS Pharmaceutical Korea as a marketing director in 2001. He became CEO of BMS Hong Kong in 2005, CEO of BMS Pharmaceutical Korea in 2006, and Executive Director of Global Marketing at BMS Headquarters in the US in 2010. Park graduated from Korea University, where he majored in agrochemistry, and received an MBA from the same university. He later completed the General Management Program at CEDEP in France.

Itzhak Krinsky, Chairman of Teva-Handok, said: “We are glad to have recruited Sun-dong Park as the new CEO of Teva-Handok. He has demonstrated his expertise and leadership both in Korea and in the global community”. He added: “We are confident that his global experience, combined with his extensive experience in the Korean market, will contribute to our business in rapidly providing Teva-Handok`s excellent products to Korean healthcare professionals and patients”.

The newly appointed CEO Park said: “Based on my knowledge and experience gained at domestic and overseas markets, I will do my very best to ensure that Teva-Handok will be well-positioned in the Korean market as soon as possible, while maintaining our commitment to improving the quality of life for Korean patients by providing top quality Teva-Handok products at affordable prices”.
Teva-Handok was launched in October 2013 as a business venture between 60-year-old trusted pharmaceutical company Handok (formerly Handok Pharmaceuticals) and Teva Pharmaceutical Industries, the world`s ninth largest pharmaceutical company and the world`s largest generic drug manufacturer. Teva owns a 51 percent stake in the business venture, and 49 percent owned by Handok. Teva-Handok`s board recently decided to raise KRW 10 billion in capital to expand investment.